RxDoctor Payments Data

Devprakash Samuel, MD

Neurology · Fort Gratiot, MINPI 1760579171

Payments from drug & device makers

$6,622in general payments, 2019–2025

Across 344 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • EMD Serono, Inc.$781
  • Biogen$418
  • Neurelis, Inc.$409
  • AbbVie$343
  • Bristol Myers Squibb$286
  • plus $3K from 36 others

What the payments were for

  • Speaking & faculty fees$621%
  • Food & beverage$6,44897%
  • Education$1122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,622 in reported general payments places this provider in the 70th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$75,179
Medicare patients
161
Services billed
465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate15$112,732
Glatiramer Acetate34$96,051
FingolimodFingolimod Hcl12$30,809
GlatopaGlatiramer Acetate13$30,516
BriviactBrivaracetam11$15,185
DilantinPhenytoin Sodium Extended16$8,807
Carbidopa-LevodopaCarbidopa/Levodopa171$6,338
Gabapentin275$4,145
Carbamazepine ErCarbamazepine18$4,086
Levetiracetam135$3,523
Propranolol Hcl ErPropranolol Hcl45$2,939
Carbidopa-Levodopa ErCarbidopa/Levodopa28$2,387
Divalproex Sodium48$2,110
Pyridostigmine Bromide12$1,982
Donepezil Hcl164$1,756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$29$112,73215 claims
UCB, Inc.Briviact$1,675$15,18511 claims
PfizerDilantin$47$8,80716 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$15$1,98212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 652 neurology providers in Michigan.

Other neurology in Fort Gratiot

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →